logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
22/12/2025
New York gold futures broke through $4440 per ounce, rising 1.21% intraday.
Latest
3 m ago
The US building price index increased by 0.22% on a weekly basis, rising for 4 consecutive weeks.
5 m ago
The main construction of the first phase of the Bailong Nuclear Power Plant has begun.
5 m ago
China Iron and Steel Association: China Minmetals Group should include domestic indexes in pricing options during negotiations with the four major mining companies.
5 m ago
AstraZeneca: Ceralasertib can be used to treat advanced non-small cell lung cancer. The overall tolerability of the combination therapy of Ceralasertib and Imfinzi is good. The safety profile is consistent with what is known for each drug, and no new safety concerns have been identified.
6 m ago
AstraZeneca: Ceralasertib can be used to treat advanced non-small cell lung cancer. The combination therapy of Ceralasertib and Imfinzi has overall good tolerability.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.